Press Release
June 9, 2020

Tropic Biosciences Raises $28.5 Million Series B Financing to Transform the Massive Tropical Agriculture Industry

The London and Cambridge Life Sciences team advised Tropic Biosciences UK Limited on the completion of a $28.5 million Series B round of equity funding, led by Temasek with participation from other new and existing investors.
Tropic’s crop products promote cultivation efficiencies, consumer health, and sustainable environmental practices. Proceeds from the largest ever funding in the UK AgriTech sector will accelerate Tropic’s growth trajectory through field trials for its novel banana and coffee varieties; further commercialization of its proprietary GEiGS technology platform; and the development of high-impact traits in rice, adding this major staple crop to its product portfolio.
Tropic Biosciences is a UK-based biotechnology company focused on utilizing advanced plant breeding and gene editing technologies to develop high-performing commercial tropical crops, namely coffee and bananas. Temasek is a global investment company headquartered in Singapore.
The Goodwin team was led by David Mardle, Elizabeth Rhodes and Roshni Thakkar with support from Curtis McCluskey
For more details about the financing, please read the press release and an article in The Business Times.